Vanflyta scores a primary with EU approval

Following US approval in the identical indication earlier this 12 months,
Japanese drugmaker Daiichi Sankyo’s (TYO: 4568) Vanflyta
(quizartinib) has now additionally been authorized within the European Union
(EU).

The drug has been licensed to be used together with normal
cytarabine and anthracycline induction and normal cytarabine
consolidation chemotherapy, adopted by Vanflyta single-agent
upkeep remedy for grownup sufferers with newly recognized
acute…

This text is accessible to registered customers, to proceed studying please register at no cost.  A free trial offers you entry to unique options, interviews, round-ups and commentary from the sharpest minds within the pharmaceutical and biotechnology house for every week. In case you are already a registered consumer please login. In case your trial has come to an finish, you possibly can subscribe right here.

Strive before you purchase

• All of the information that strikes the needle in pharma and biotech.
• Unique options, podcasts, interviews, information analyses and commentary from our world community of life sciences reporters.
• Obtain The Pharma Letter every day information bulletin, free ceaselessly.

Change into a subscriber

• Unfettered entry to industry-leading information, commentary and evaluation in pharma and biotech.
• Updates from scientific trials, conferences, M&A, licensing, financing, regulation, patents & authorized, government appointments, industrial technique and monetary outcomes.
• Every day roundup of key occasions in pharma and biotech.
• Month-to-month in-depth briefings on Boardroom appointments and M&A information.
• Select from an economical annual package deal or a versatile month-to-month subscription.